{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:29:35Z","timestamp":1761128975359,"version":"3.38.0"},"reference-count":41,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2011,12,29]],"date-time":"2011-12-29T00:00:00Z","timestamp":1325116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>Abstract\u00a0<\/jats:title><jats:p>Hepatitis<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>virus genotype 4 (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u20104) is the most common type of hepatitis<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) in the<jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>iddle<jats:styled-content style=\"fixed-case\">E<\/jats:styled-content>ast and<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>frica, in particular<jats:styled-content style=\"fixed-case\">E<\/jats:styled-content>gypt. Since the development of new protease inhibitors, the response of<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u20104 to the standard regimen of treatment (pegylated interferon\/ribavirin) lags behind other genotypes and has become the most resistant type to treat. The development of therapeutic strategies for all patients with<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u20104 whether they are na\u00efve, have experienced a virological breakthrough, are relapsers or non\u2010responders is still a considerable challenge. New types of interferon (<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>onsensus Interferon,<jats:styled-content style=\"fixed-case\">Y<\/jats:styled-content>\u2010shaped, Albinterferon\u2026) and new direct action antiviral drugs (Nitazoxanide, Vit.<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>, other) may improve the treatment of patients with<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u20104. The<jats:styled-content style=\"fixed-case\">IL28B CC<\/jats:styled-content>polymorphism may be associated with sustained virological response.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2011.02704.x","type":"journal-article","created":{"date-parts":[[2011,12,29]],"date-time":"2011-12-29T17:38:09Z","timestamp":1325180289000},"page":"146-150","source":"Crossref","is-referenced-by-count":24,"title":["The future for the treatment of genotype 4 chronic hepatitis<scp>C<\/scp>"],"prefix":"10.1111","volume":"32","author":[{"given":"G.","family":"Esmat","sequence":"first","affiliation":[{"name":"Endemic Medicine Department Cairo University Cairo Egypt"},{"name":"Tropical Medicine Department National Hepatology and Tropical Medicine Research Institute (NHTMRI) Cairo Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"El Raziky","sequence":"additional","affiliation":[{"name":"Endemic Medicine Department Cairo University Cairo Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"El Kassas","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department National Hepatology and Tropical Medicine Research Institute (NHTMRI) Cairo Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hassany","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department National Hepatology and Tropical Medicine Research Institute (NHTMRI) Cairo Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.","family":"Gamil","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department National Hepatology and Tropical Medicine Research Institute (NHTMRI) Cairo Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.011"},{"issue":"5","key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of hepatitis C","volume":"5","author":"Hoofnagle JH","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.32.4.884-892.1994"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/315786"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.1995.tb00044.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199905)58:1<44::AID-JMV6>3.0.CO;2-U"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200207000-00017"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890470423"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199607)49:3<178::AID-JMV4>3.0.CO;2-1"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80275-9"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00350-9"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80192-X"},{"key":"e_1_2_7_14_1","first-page":"1","article-title":"NIH Consensus Statement on Management of Hepatitis C: 2002","volume":"19","author":"NIH","year":"2002","journal-title":"NIH Consens State Sci Statements"},{"key":"e_1_2_7_15_1","first-page":"364A","article-title":"Optimized virological response in genotype 4 chronic hepatitis C patients treated with peginterferon alfa\u20102a (40KD) (pegasys\u00ae) in combination with ribavirin (RBV)","volume":"2","author":"Diago M","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0270-9139(03)81034-0"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2004.0976.x"},{"key":"e_1_2_7_18_1","first-page":"364A","article-title":"Treatment with PEG\u2010interferon alfa\u20102b (PEG\u2010IFN) plus ribavirin compared to interferon alfa\u20102b (IFN alfa\u20102b)plus ribavirin on subjects with chronic hepatitis C infected with HCV genotype 4","volume":"2","author":"Esmat G","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.40077.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.11.016"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02385.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22871"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1746-3"},{"issue":"4","key":"e_1_2_7_24_1","first-page":"256A","article-title":"Sustained virologic response with albinterferon alfa\u20102b plus ribavirin treatment in prior interferon therapy nonresponders [abstract 51]","volume":"46","author":"Nelson D","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_7_25_1","unstructured":"Mohamed K.Ashour Maissa E.Elraziky WafaaA et\u00a0al.Safety Dosage and Efficacy of a Novel Y shaped molecule of Pegylated Interferon alpha 2a for Treatment of Chronic HCV. Accepted poster (AASLD 2011)."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02411.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2411"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806104"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908014"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(09)60012-X"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00699-08"},{"key":"e_1_2_7_32_1","article-title":"High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1\/4 patients treated with RG7128 plus PegIFN alfa\u20102a (40KD)\/RBV: Planned Week 12interim analysis from the PROPEL study","volume":"52","author":"Jensen DM","year":"2010","journal-title":"Hepatology"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.07.056"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03781.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31800-9"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22835"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.072"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.09.009"},{"volume-title":"Presented at The Liver Meeting 2009: 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): Abstract LB20","author":"Abu\u2010Mouch SM","key":"e_1_2_7_39_1"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.034801-0"},{"key":"e_1_2_7_41_1","unstructured":"H\u00e9zodeC HirschfieldGM GhesquiereW et\u00a0al.A NS5A replication complex inhibitor combined with PEG\u2010Interferon\u2010Alpha\u20102A and ribavirin in treatment\u2010na\u00efve HCV\u2010Genotype 1 or 4 subjects: The phase 2B momentum study week 12 results. Accepted poster (AASLD 2011)."},{"journal-title":"J Hepatol","article-title":"IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C","author":"Asselah T","key":"e_1_2_7_42_1"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2011.02704.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2011.02704.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T02:31:26Z","timestamp":1742178686000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2011.02704.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,29]]},"references-count":41,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1478-3231.2011.02704.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02704.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"type":"print","value":"1478-3223"},{"type":"electronic","value":"1478-3231"}],"subject":[],"published":{"date-parts":[[2011,12,29]]}}}